(Photo Courtesy: www.secretstooutsourcingservices.wordpress.com)
At $2.5-3.1 billion, pharmaceutical outsourcing market (excluding contract manufacturing services) accounts for about 75 percent of the India's medical process outsourcing (MPO) segment which is currently estimated at $3.3-4.2 bn, according to ASSOCHAM-EY joint study.
"While the payer outsourcing market constitutes $700-900 million of India's MPO market, the provider market accounts for the remaining share of about $100-200 mn," noted the study titled ‘Medical Process Outsourcing in India,' jointly conducted by The Associated Chambers of Commerce and Industry of India (ASSOCHAM) and global professional services organization EY.
The recent US regulation on Patient Protection and Affordable Care Act (PPACA) together with the proposed introduction of ICD-10 standards have given impetus to the Indian MPO market.
Besides, domestic players are also gradually moving up the value chain in terms of service offerings while maintaining their cost competitiveness.
"All of these combined will give a boost to the MPO market, with payer BPO market likely to grow at about 10 percent year-on-year (Y-o-Y) in the next three to four years globally, provider outsourcing at more than 30 percent during 2011-2016, and the Contract Research Organizations (CROs) market at 18-20 percent in the coming years," highlighted the study.
"We believe that there has been an ample push from healthcare payers, providers and pharmaceutical companies to move non-core processes to third-party service providers, and India has been one of the leading destinations for outsourcing in this space," said Mr D S Rawat, secretary general of ASSOCHAM.